A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery

Brain

Volumn 130, Issue 11, 2007, Pages 2898-2914

  Mounayar, Stéphanie ^a,b,c   Boulet, Sabrina ^a,d,e   Tandé, Dominique ^a,b,c   Jan, Caroline ^a,b,c   Pessiglione, Mathias ^a,b,c   Hirsch, Etienne C ^a,b,c   Féger, Jean ^a,b,c   Savasta, Marc ^a,d,e   François, Chantal ^a,b,c   Tremblay, Léon ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIV GRENOBLE ALPES   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Behaviour; Compensation; Immunohistology; Monkey; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; SEROTONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC SYSTEM; DRUG INTOXICATION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION; SEROTONINERGIC SYSTEM;

EID: 35648996914     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awm208     Document Type: Article

References (66)

1. Agid Y, Javoy F, Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nat New Biol 1973; 245: 150-1.
2. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionnaly segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 1986; 9: 357-81.
3. Altar CA, Marien MR, Marshall JF. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J Neurochem 1987; 48: 390-9.
4. Beal MF. Experimental models of Parkinson's disease. Nat Rev Neurosci 2001; 2: 325-34.
5. Bergman H, Raz A, Feingold A, Nini A, Nelken I, Hansel D, et al. Physiology of MPTP tremor. Mov Disord 1998; 13 (Suppl 3): 29-34.
6. Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subthalamic nucleus. 2. Neuronal activity in the MPTP model of Parkinsonism. J Neurophysiol 1994; 72: 507-20.
7. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20: 415-55.
8. Bezard E, Bioulac B, Gross CE. Glutamatergic compensatory mechanisms in experimental parkinsonism. Prog Neuro Psych Biol Psych 1998; 22: 609-23.
9. Bezard E, Crossman AR, Gross CE, Brotchie JM. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB J 2001; 15: 1092-4.
10. Bezard E, Gross CE. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog Neurobiol 1998; 55: 93-116.
11. Bezard E, Imbert C, Deloire X, Bioulac B, Gross CE. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res 1997; 766: 107-12.
12. Boraud T, Bezard E, Bioulac B, Gross CE. From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control. Prog Neurobiol 2002; 66: 265-83.
13. Boulet S, Mounayar S, Bertrand A, Poupard A, Jan C, Pessiglione M, et al. Compensatory mechanisms on MPTP-treated monkeys with recovery of parkinsonian motor symptoms: II. Biochemical approach by microdialysis. Soc Neurosci Abstr 2005; 87: 14.
14. Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear plasy. Ann Neurol 1990; 28: 547-55.
15. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13: 281-5.
16. Dickson JM, Grunewald RA. Somatic symptom progression in idiopathic Parkinson's disease. Parkinsonism Relat Disord 2004; 10: 487-92.
17. Eidelberg E, Brooks BA, Morgan WW, Walden JG. Variability and functional recovery in the N-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine model of parkinsonism in monkeys. Neuroscience 1986; 18: 817-22.
18. Elsworth JD, Deutch AY, Redmond DEJ, Taylor JR, Sladek JR Jr, Roth RH. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates: biochemical changes in striatal regions. Neuroscience 1989; 33: 323-31.
19. Elsworth JD, Taylor JR, Sladek JR, Collier TJ, Redmond DE, Roth RH. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 2000; 95: 399-408.
20. Finkelstein DI, Stanic D, Parish CL, Tomas D, Dickson K, Horne MK. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 2000; 97: 99-112.
21. Flaherty AW, Graybiel AM. Input-output organization of the sensorimotor striatum in the squirrel monkey. J Neurosci 1994; 14: 599-610.
22. Francois C, Yelnik J, Tande D, Agid Y, Hirsch EC. Dopaminergic cell group A8 in the monkey: anatomical organization and projections to the striatum. J Comp Neurol 1999; 414: 334-47.
23. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993; 34: 423-31.
24. Gaspar P, Febvret A, Colombo J. Serotonergic sprouting in primate MPTP-induced hemiparkinsonism. Exp Brain Res 1993; 96: 100-6.
25. Goetz CG, Stebbins GT, Shale HM, Lang AE, Chernik DA, Chmura TA, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter-and intrarater reliability assessment. Mov Disord 1994; 9: 390-4.
26. Guehl D, Pessiglione M, Francois C, Yelnik J, Hirsch EC, Feger J, et al. Tremor-related activity of neurons in the 'motor' thalamus: changes in firing rate and pattern in the MPTP vervet model of parkinsonism. Eur J Neurosci 2003; 17: 2388-400.
27. Haber SN, Lynd E, Klein C, Groenewegen HJ. Topographic organization of the ventral striatal efferent projections in the rhesus monkey: an anterograde tracing study. J Comp Neurol 1990; 293: 282-98.
28. Hantraye P, Varastet M, Peschanski M, Riche D, Cesaro P, Willer JC, et al. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience 1993; 53: 169-78.
29. Herrero MT, Perez-Otano I, Oset C, Kastner A, Hirsch EC, Agid Y, et al. GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys. Neuroscience 1993; 56: 965-72.
30. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
31. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1987; 45: 19-34.
32. Iravani MM, Jackson MJ, Kuoppamaki M, Smith LA, Jenner P. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates. J Neurosci 2003; 23: 9107-15.
33. Jan C, François C, Yelnik J, Tande D, Agid Y, Hirsch EC. Dopaminergic innervation of the pallidum in the normal state, MPTP-treated monkeys and Parkinsonian patients. Eur J Neurosci 2000; 12: 4525-35.
34. Jan C, Pessiglione M, Tremblay L, Tande D, Hirsch EC, Francois C. Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP-treated monkeys. Eur J Neurosci 2003; 18: 2082-6.
35. Jellinger KA. Post mortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999; 56: 1-29.
36. Jenner P, Rupniak NMJ, Rose S, Kelly E, Kilpatrick G, Lees A, et al. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 1984; 50: 85-90.
37. Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B. Clinical characteristics in early Parkinson's disease is a central california population-based study. Mov Disord 2005; 20: 1133-42.
38. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the sriatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988; 318: 876-80.
39. Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F. Unified Parkinson's disease Rating scale characteristics and structure. The cooperative Multicentric Group. Mov Disord 1994; 9: 76-83.
40. Matsumoto N, Hanakawa T, Maki S, Graybiel AM, Kimura M. Nigrostriatal dopamine system in learning to perform sequential motor tasks in a predictive manner. J Neurophysiol 1999; 82: 978-98.
41. Mounayar S, Boulet S, Tande D, Pessiglione M, Jan C, Hirsch E, et al. Compensatory mechanisms on MPTP-treated monkeys with recovery of parkinsonian motor symptoms:I. Behavioral and immunohistological approaches. Soc Neurosci Abstr 2005; 87: 13.
42. Nakamura K, Hikosaka O. Role of dopamine in the primate caudate nucleus in reward modulation of saccades. J Neurosci 2006; 26: 5360-9.
43. Parent A, Hazrati LN. Functional anatomy of the basal ganglia.2. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Rev 1995; 20: 128-54.
44. Pessiglione M, Guehl D, Agid Y, Hirsch EC, Feger J, Tremblay L. Impairment of context-adapted movement selection in a primate model of presymptomatic Parkinson's disease. Brain 2003; 126: 1392-408.
45. Pessiglione M, Guehl D, Hirsch EC, Feger J, Tremblay L. Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism. I. Effects of task complexity. Eur J Neurosci 2004a; 19: 426-36.
46. Pessiglione M, Guehl D, Jan C, Francois C, Hirsch EC, Feger J, et al. Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism: II. Effects of reward preference. Eur J Neurosci 2004b; 19: 437-46.
47. Pessiglione M, Guehl D, Rolland AS, Francois C, Hirsch EC, Feger J, et al. Thalamic neuronal activity in dopamine-depleted primates: evidence for a loss of functional segregation within basal ganglia circuits. J Neurosci 2005; 25: 1523-31.
48. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 2001; 76: 1265-74.
49. Redmond DE, Roth RH, Sladek JR. MPTP produces classic parkinsonian syndrome in African green monkeys. Soc Neurosci Abstr 1985; 11: 166.
50. Rozas G, Liste I, Guerra MJ, Labandeiragarcia JL. Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 1998; 245: 151-4.
51. Schelosky L, Poewe W. Topographical onset and progression of motor symptoms in idiopathic Parkinson's disease. Mov Disord 1990; 5 (S1): 13. Schneider JS, Kovelowski CJI. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 1990; 519: 122-8.
52. Schneider JS, Pope-Coleman A. Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 1995; 4: 245-55.
53. Schneider JS, Rothblat DS, DiStefano L. Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism. Brain Res 1994; 643: 86-91.
54. Schroeder JA, Schneider JS. GABA(A) and mu-opioid receptor binding in the globus pallidus and endopeduncular nucleus of animals symptomatic for and recovered from experimental Parkinsonism. Brain Res 2002; 947: 284-9.
55. Schultz W, Tremblay L, Hollerman JR. Changes in behavior-related neuronal activity in the striatum during learning. Trends Neurosci 2003; 26: 321-8.
56. Snyder GL, Keller RW Jr, Zigmond MJ. Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals. J Pharmacol Exp Ther 1990; 253: 867-76.
57. Song DD, Haber SN. Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting. J Neurosci 2000; 20: 5102-14.
58. Takeuchi Y, Sawada T, Blunt S, Jenner P, Marsden CD. Effects of 6-hydroxydopamine lesions of the nigrostriatal pathway on striatal serotonin innervation in adult rats. Brain Res 1991; 562: 301-5.
59. Taylor JR, Elsworth JD, Roth RH, Sladek JR, Redmond DE. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 1997; 81: 745-55.
60. Tremblay L, Filion M, Bedard PJ. Responses of pallidal neurons to striatal stimulation II. in monkeys with MPTP-induced parkinsonism. Brain Res 1989; 498: 17-33.
61. Uitti RJ, Baba Y, Szolek ZK, Putzke DJ. Defining the Parkinson's disease phenotype: initial symptoms and baseline characteristics in a clinical cohort. Parkinsonism Relat Disord 2005; 11: 139-45.
62. Vidailhet M, Marconi R, Gouider-Khouja N, Agid Y. Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot? Neurology 1994; 44: 1613-6.
63. Whone AL, Moore RY, Piccini PP, Brooks DJ. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol 2003; 53: 206-13.
64. Zhou FC, Bledsoe S, Murphy J. Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 1991; 556: 108-16.
65. Zigmond MJ. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism. Neurobiol Dis 1997; 4: 247-53.
66. Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol 1984; 41: 856-61.